{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:45:53Z","timestamp":1793022353960,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jgo.2022.05.013","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T17:15:16Z","timestamp":1654276516000},"page":"997-1002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study"],"prefix":"10.1016","volume":"13","author":[{"given":"Bert N.","family":"Storm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanieh","family":"Abedian Kalkhoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik B.","family":"Wilms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pepijn","family":"Brocken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Codrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Houtsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanneke E.A.","family":"Portielje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke","family":"de Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"van der Ziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederiek","family":"van den Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loes E.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10027","key":"10.1016\/j.jgo.2022.05.013_bb0005","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jgo.2022.05.013_bb0010","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jgo.2022.05.013_bb0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jgo.2022.05.013_bb0020","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2022.05.013_bb0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2018.06.033","article-title":"Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer","volume":"101","author":"Liu","year":"2018","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jgo.2022.05.013_bb0030","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/14740338.2020.1736554","article-title":"The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer","volume":"19","author":"Mazarico Gallego","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.jgo.2022.05.013_bb0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14740338.2017.1267725","article-title":"The safety of nivolumab for the treatment of advanced non-small cell lung cancer","volume":"16","author":"Metro","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jgo.2022.05.013_bb0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jgo.2022.05.013_bb0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-publhealth-032315-021353","article-title":"Using electronic health records for population health research: a review of methods and applications","volume":"37","author":"Casey","year":"2016","journal-title":"Annu Rev Public Health"},{"issue":"3","key":"10.1016\/j.jgo.2022.05.013_bb0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jgo.2017.02.001","article-title":"Immunotherapy comes of age: immune aging & checkpoint inhibitors","volume":"8","author":"Elias","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2022.05.013_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.exger.2017.10.024","article-title":"Age and immunity: what is \u201cimmunosenescence\u201d?","volume":"105","author":"Pawelec","year":"2018","journal-title":"Exp Gerontol"},{"issue":"9","key":"10.1016\/j.jgo.2022.05.013_bb0060","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with Nivolumab in patients with advanced non-small cell lung Cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"suppl_4","key":"10.1016\/j.jgo.2022.05.013_bb0065","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2022.05.013_bb0070","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00280-020-04055-7","article-title":"Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer","volume":"85","author":"Yamaguchi","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jgo.2022.05.013_bb0075","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.09.011","article-title":"Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer","volume":"123","author":"Grossi","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jgo.2022.05.013_bb0080","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.10010","article-title":"FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers","volume":"34","author":"Singh","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2022.05.013_bb0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00432-019-03072-1","article-title":"Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged \u226575 years) with non-small cell lung cancer","volume":"146","author":"Imai","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jgo.2022.05.013_bb0090","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","article-title":"Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies","volume":"135","author":"Nosaki","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2022.05.013_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100042","article-title":"A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study","volume":"6","author":"Gomes","year":"2021","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.jgo.2022.05.013_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001865","article-title":"Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer","volume":"9","author":"Ardizzoni","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2022.05.013_bb0105","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/JU.0000000000001768","article-title":"Safety and efficacy of Atezolizumab in under studied populations with pretreated urinary tract carcinoma: subgroup analyses of the SAUL study in real-world practice","volume":"206","author":"Merseburger","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.jgo.2022.05.013_bb0110","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.3390\/curroncol28050283","article-title":"Safety of immune checkpoint inhibitors in elderly patients: an observational study","volume":"28","author":"Paderi","year":"2021","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2022.05.013_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2022.05.013_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0300891620926244","article-title":"Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study","volume":"107","author":"Cavaille","year":"2021","journal-title":"Tumori."},{"issue":"1","key":"10.1016\/j.jgo.2022.05.013_bb0125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program","volume":"7","author":"Verzoni","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2022.05.013_bb0130","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11096-018-0590-3","article-title":"The differences in the assessments of side effects at an oncology outpatient clinic","volume":"40","author":"Bayraktar-Ekincioglu","year":"2018","journal-title":"Int J Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.jgo.2022.05.013_bb0145","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1745-6215-13-138","article-title":"Drug safety assessment in clinical trials: methodological challenges and opportunities","author":"Singh","year":"2012","journal-title":"Trials."},{"issue":"11","key":"10.1016\/j.jgo.2022.05.013_bb0150","doi-asserted-by":"crossref","first-page":"e1165","DOI":"10.1634\/theoncologist.2018-0737","article-title":"Italian cohort of Nivolumab expanded access program in squamous non-small cell lung cancer: results from a real-world population","volume":"24","author":"Crin\u00f2","year":"2019","journal-title":"Oncologist."}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406822001345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406822001345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:55:18Z","timestamp":1761818118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406822001345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1879406822001345"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2022.05.013","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2022.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}